Atezolizumab may improve survival when it’s added to nab-paclitaxel but not paclitaxel, studies suggest.
From the Journals
Data suggest fewer people are dying from stomach cancer, but in some countries, the risk of colorectal cancer death is increasing or declining...
Abemaciclib improved invasive disease-free survival when added to endocrine therapy.
Sacituzumab govitecan prolonged progression-free and overall survival.